ABG
PBYI icon

Ally Bridge Group’s Puma Biotechnology PBYI Stock Holding History

Ally Bridge Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-64,295
Closed -$152K – 38
2022
Q3 		$152K Buy
+64,295
New +$188K 0.1% 38

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Ally Bridge Group's PBYI Position: Q4 2022 in Review

Ally Bridge Group sold out of Puma Biotechnology (PBYI) in Q4 2022, closing a stake of 64,295 shares — an estimated $152K sold.

Ally Bridge Group first reported a position in PBYI in Q3 2022 and held it in 1 quarter. The position peaked at $152K in Q3 2022. 88 funds tracked by Wall St. Rank hold PBYI as of Q4 2022.

  • Ally Bridge Group reported no remaining Puma Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Ally Bridge Group sold 64,295 Puma Biotechnology shares in Q4 2022, an estimated $152K.
  • Ally Bridge Group first reported a position in Puma Biotechnology in Q3 2022 and held it in 1 quarter.
  • Ally Bridge Group's Puma Biotechnology position peaked at $152K in Q3 2022.
  • 88 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2022.

Based on Ally Bridge Group's 13F filing for Q4 2022, filed 14 Feb 2023.